Pfizer Secures Up to $65M Upfront in Collaboration Potentially Worth $850M+
Pfizer has entered a multi-year collaboration with Cartography Biosciences to apply its ATLAS and SUMMIT discovery platforms for tumor-selective antigen identification. Under the agreement, Pfizer may opt in on multiple antigens, with Cartography eligible for up to $65 million upfront and total deal value exceeding $850 million plus tiered royalties.
1. Pfizer Invites Public to Webcast CEO Discussion at Healthcare Conference
Pfizer has scheduled a live webcast of Chairman and Chief Executive Officer Albert Bourla’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. Investors and the general public may access the live stream and register beginning today via the company’s investor relations website. A transcript and replay of the discussion will be posted within 24 hours of the event and remain available for at least 90 days, ensuring broad access to insights on Pfizer’s strategic priorities, pipeline progress, and financial outlook. This event underscores Pfizer’s commitment to transparency and direct engagement with the investment community.